FDA approves first interchangeable biosimilar product for Humira

The Food and Drug Administration today approved the first interchangeable biosimilar product for Humira, a monoclonal antibody used to treat certain inflammatory diseases. The product (Cyltezo) is approved to treat certain adult and pediatric patients with arthritis or Crohn's disease, and certain adults with ulcerative colitis or psoriasis.